[go: up one dir, main page]

BR0005765A - Combinação de inibidores de aldose redutase e agentes anti-hipertensivos para o tratamento de complicações diabéticas - Google Patents

Combinação de inibidores de aldose redutase e agentes anti-hipertensivos para o tratamento de complicações diabéticas

Info

Publication number
BR0005765A
BR0005765A BR0005765-7A BR0005765A BR0005765A BR 0005765 A BR0005765 A BR 0005765A BR 0005765 A BR0005765 A BR 0005765A BR 0005765 A BR0005765 A BR 0005765A
Authority
BR
Brazil
Prior art keywords
treatment
diabetic
aldose reductase
combination
prodrug
Prior art date
Application number
BR0005765-7A
Other languages
English (en)
Inventor
Banavara Lakshman Mylari
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0005765A publication Critical patent/BR0005765A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Patente de Invenção: <B>"COMBINAçãO DE INIBIDORES DE ALDOSE REDUTASE E AGENTES ANTI-HIPERTENSIVOS PARA O TRATAMENTO DE COMPLICAçõES DIABéTICAS"<D>. Esta invenção é dirigida a métodos, composições farmacêuticas e kits compreendendo um inibidor de aldose redutase (ARI), uma sua pró-droga, ou um sal farmaceuticamente aceitável do referido ARI ou da referida pró-droga; um agente anti-hipertensivo, uma sua pró-droga, ou um sal farmaceuticamente aceitável do referido agente anti-hipertensivo ou da referida pró-droga. Esta invenção ainda se dirige a métodos que utilizam essas composições farmacêuticas para o tratamento de complicações diabéticas tais como a neuropatia diabética, nefropatia diabética, retinopatia diabética, enfarte de miocárdio, cataratas e cardiomiopatia diabética.
BR0005765-7A 1999-12-07 2000-12-07 Combinação de inibidores de aldose redutase e agentes anti-hipertensivos para o tratamento de complicações diabéticas BR0005765A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16938099P 1999-12-07 1999-12-07

Publications (1)

Publication Number Publication Date
BR0005765A true BR0005765A (pt) 2001-07-17

Family

ID=22615435

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0005765-7A BR0005765A (pt) 1999-12-07 2000-12-07 Combinação de inibidores de aldose redutase e agentes anti-hipertensivos para o tratamento de complicações diabéticas

Country Status (5)

Country Link
US (2) US20020068740A1 (pt)
EP (1) EP1106210A3 (pt)
JP (1) JP2001163805A (pt)
BR (1) BR0005765A (pt)
CA (1) CA2327575A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
WO2002098429A1 (en) * 2001-06-07 2002-12-12 Pfizer Products Inc. Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
US20040192699A1 (en) * 2001-07-02 2004-09-30 Santen Pharmaceutical Co., Ltd. Optic nerve protecting agents containing alpha1 receptor blocker as active ingredient
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2831446B1 (fr) 2001-10-26 2004-03-05 Sanofi Synthelabo Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
WO2003059372A2 (en) * 2001-12-29 2003-07-24 Novo Nordisk A/S Combined use of a glp-1 compound and a modulator of diabetic late complications
JP2005533822A (ja) * 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド 臭化水素酸カルベジロール
BR0312102A (pt) * 2002-06-27 2007-05-29 Sb Pharmco Inc sais de fosfato de carvedilol e/ou seus solvatos, composições correspondentes, e/ou métodos de tratamento
JP2007015924A (ja) * 2003-06-12 2007-01-25 Sanwa Kagaku Kenkyusho Co Ltd 抗癌剤耐性を克服する薬剤及びそのスクリーニング方法
WO2005037284A1 (en) * 2003-10-15 2005-04-28 Pfizer Products Inc. Sorbitol dehydrogenase inhibitor and hypertensive agent combinations
ES2662903T3 (es) * 2003-11-25 2018-04-10 Smithkline Beecham (Cork) Limited Base libre de carvedilol, sales, formas anhidras o solvato de la misma, composiciones farmacéuticas correspondientes, formulaciones de liberación controlada, y procedimientos de tratamiento o administración
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
EP1686986A4 (en) * 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
US7910615B2 (en) 2004-01-30 2011-03-22 Sanwa Kagaku Kenkyusho Co., Ltd. Prophylactic or therapeutic agent for diabetic maculopathy
ES2282062T1 (es) 2004-06-04 2007-10-16 Teva Pharmaceutical Industries Ltd. Composicion farmaceutica que contiene irbesartan.
WO2006019851A1 (en) * 2004-07-23 2006-02-23 Eli Lilly And Company Methods for diagnosing and treating diabetic microvascular complications
JP4954085B2 (ja) * 2004-12-06 2012-06-13 メディシノバ， インコーポレイテッド 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト
US7832364B2 (en) * 2006-12-14 2010-11-16 Texaco Inc. Heat transfer unit for steam generation and gas preheating
WO2008094571A1 (en) * 2007-01-30 2008-08-07 Avigen, Inc. Methods for treating acute and subchronic pain
US20080287402A1 (en) * 2007-05-03 2008-11-20 Johnson Kirk W Use of a glial attenuator to prevent amplified pain responses caused by glial priming
WO2010011922A2 (en) * 2008-07-25 2010-01-28 Bionevia Pharmaceuticals, Inc. Novel crystalline salts of epalrestat
US8697735B2 (en) 2008-07-25 2014-04-15 Bionevia Pharmaceuticals, Inc. Solid forms of epalrestat
CN102216281B (zh) 2008-09-06 2014-11-05 碧奥尼维亚制药股份有限公司 依帕司他的新胆碱共结晶
WO2010085014A1 (en) 2009-01-23 2010-07-29 Hanmi Pharm. Co., Ltd. Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
RU2013135224A (ru) 2011-01-20 2015-03-10 Бионевиа Фармасьютикалс Инк. Композиции с модифицированным высвобождением эпалрестата или его производных и способы их использования
US9308165B2 (en) 2013-08-22 2016-04-12 Therapeutic Vision, Inc. Composition for treating ocular effects of diabetes
WO2019023648A1 (en) 2017-07-28 2019-01-31 Applied Therapeutics Inc. COMPOSITIONS AND METHODS FOR TREATING GALACTOSEMIA
MX2021013511A (es) 2019-05-07 2022-02-23 Univ Miami Tratamiento y deteccion de neuropatias heredadas y trastornos asociados.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
IL124236A (en) * 1997-05-05 2003-01-12 Pfizer Pharmaceutical composition for treating or reversing diabetic cardiomyopathy comprising aldose reductase inhibitor

Also Published As

Publication number Publication date
US20030050301A1 (en) 2003-03-13
US20020068740A1 (en) 2002-06-06
CA2327575A1 (en) 2001-06-07
EP1106210A3 (en) 2003-12-03
JP2001163805A (ja) 2001-06-19
EP1106210A2 (en) 2001-06-13

Similar Documents

Publication Publication Date Title
BR0005765A (pt) Combinação de inibidores de aldose redutase e agentes anti-hipertensivos para o tratamento de complicações diabéticas
CY1120313T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει βιταμινη d και κορτικοστεοειδες
BR0002953A (pt) Composições e tratamento para complicações diabéticas
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
MA30765B1 (fr) Derives innovants du thiophene
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
HUP0004318A2 (hu) Atorvastatint és egy vérnyomáscsökkentő szert tartalmazó gyógyszerkészítmény
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
ECSP055783A (es) Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevención de diabetes
BR0115411A (pt) Combinações sinergìsticas compreendendo um inibidor de renina para doenças cardiovasculares
PA8506101A1 (es) Uso de un compuesto acat para fabricar una composicion farmaceutica
GT199700009AA (es) Terapia combinada para la osteoporosis
MA29568B1 (fr) Composes d&#39;azaindazole et methodes d&#39;utilisation desdits composes
PT1305286E (pt) Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento
BR9810520A (pt) Inibidor do fator xa isolado ou em combinação com um anti-agregador plaquetário, contra a trambose arterial
MA26965A1 (fr) Association d&#39;agonistes de gaba et d&#39;inhibiteurs d&#39;aldose-reductase.
PT1115701E (pt) Ureias de arilsulfonanilida
BR9813699A (pt) Combinação eficaz para o tratamento da impotência
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
BRPI0414558A (pt) composição farmacêutica compreendendo um antagonista do receptor p2x7 e uma droga antiinflamatória não esteróide
BRPI0509074A (pt) composições farmacêuticas compreendendo agonistas do receptor da tiróide
BR9809848A (pt) Composição
EP1106184A3 (en) Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
BR0002933A (pt) Tratamento para complicações diabéticas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1925 DE 27/11/2007.